Cargando…
Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review
Most pituitary tumors are considered benign adenomas, and only 0.1%–0.2% of them present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary adenomas (PAs) lie between benign adenomas and true malignant PCs and are defined as aggressive-invasive PAs, characterized by a hig...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635636/ https://www.ncbi.nlm.nih.gov/pubmed/34869016 http://dx.doi.org/10.3389/fonc.2021.773905 |